GS-5423

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford

Conditions

HIVHIV-1-infection

Phase 1

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

RecruitingNCT06071767

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1-infection

Start: 2024-04-01End: 2029-08-01Target: 36Updated: 2026-02-09

Phase 2

Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV

RecruitingNCT07054931

University of OxfordHIV

Start: 2025-09-05End: 2028-06-30Target: 48Updated: 2026-01-21

Related Papers

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Nature Communications2025-03-0416 citations